Geron Co. (NASDAQ:GERN) Short Interest Update

Geron Co. (NASDAQ:GERN - Get Free Report) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 45,630,000 shares, a decline of 21.9% from the February 28th total of 58,410,000 shares. Approximately 7.8% of the company's stock are short sold. Based on an average trading volume of 15,110,000 shares, the short-interest ratio is presently 3.0 days.

Hedge Funds Weigh In On Geron

Large investors have recently added to or reduced their stakes in the company. Alternative Investment Advisors LLC. increased its position in shares of Geron by 13.3% during the third quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company's stock valued at $101,000 after purchasing an additional 2,612 shares during the period. Rovin Capital UT ADV increased its holdings in Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 3,660 shares during the period. Xponance Inc. raised its stake in shares of Geron by 12.9% in the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company's stock valued at $150,000 after buying an additional 4,829 shares in the last quarter. KBC Group NV lifted its holdings in shares of Geron by 45.1% during the 4th quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 7,592 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Geron during the 4th quarter valued at about $28,000. Institutional investors and hedge funds own 73.71% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on GERN shares. Stifel Nicolaus reduced their price objective on shares of Geron from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Scotiabank reduced their price target on Geron from $6.00 to $4.00 and set a "sector outperform" rating for the company in a research report on Thursday, February 27th. B. Riley lowered Geron from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $3.50 to $2.00 in a report on Thursday, February 27th. Barclays restated an "overweight" rating and issued a $4.00 target price (down from $9.00) on shares of Geron in a report on Thursday, February 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $5.00 target price on shares of Geron in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.75.

Geron Stock Performance

GERN stock traded up $0.10 on Wednesday, reaching $1.58. 15,266,630 shares of the company were exchanged, compared to its average volume of 11,394,052. The firm has a market capitalization of $1.00 billion, a PE ratio of -4.92 and a beta of 0.54. Geron has a 12 month low of $1.45 and a 12 month high of $5.34. The stock's fifty day moving average price is $2.24 and its 200 day moving average price is $3.33. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million. On average, research analysts anticipate that Geron will post -0.25 EPS for the current fiscal year.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.